On Thursday, Harrow received an upgrade to its Relative Strength (RS) Rating, from 64 to 79.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary rating tracks price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks often have an RS Rating north of 80 in the early stages of their moves. See if Harrow can continue to show renewed price strength and clear that threshold.
Harrow is now considered extended and out of buy range after clearing a 20.31 buy point in a third-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Harrow reported 0% earnings growth last quarter, while sales growth came in at 84%. Look for the next report on or around May 19.
Harrow holds the No. 50 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
